Join Growin Stock Community!

Ardelyx, inc.ARDX.US Overview

US StockHealthcare
(No presentation for ARDX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ARDX AI Insights

ARDX Overall Performance

ARDX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ARDX Recent Performance

-2.39%

Ardelyx, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ARDX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ARDX Key Information

ARDX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ARDX Profile

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Price of ARDX

ARDX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ARDX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.25
PE Ratio (TTM)
-
Forward PE
42.73
PS Ratio (TTM)
3.91
PB Ratio
10.43
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
90.29%
Net Margin
-15.12%
Revenue Growth (YoY)
22.09%
Profit Growth (YoY)
29.93%
3-Year Revenue Growth
41.52%
3-Year Profit Growth
40.75%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.25
PE Ratio (TTM)
-
Forward PE
42.73
PS Ratio (TTM)
3.91
PB Ratio
10.43
Price-to-FCF
-
Gross Margin
90.29%
Net Margin
-15.12%
Revenue Growth (YoY)
22.09%
Profit Growth (YoY)
29.93%
3-Year Revenue Growth
41.52%
3-Year Profit Growth
40.75%
  • When is ARDX's latest earnings report released?

    The most recent financial report for Ardelyx, inc. (ARDX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ARDX's short-term business performance and financial health. For the latest updates on ARDX's earnings releases, visit this page regularly.

  • What is the operating profit of ARDX?

    According to the latest financial report, Ardelyx, inc. (ARDX) reported an Operating Profit of 5.1M with an Operating Margin of 4.07% this period, representing a decline of 37.24% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ARDX's revenue growth?

    In the latest financial report, Ardelyx, inc. (ARDX) announced revenue of 125.22M, with a Year-Over-Year growth rate of 7.82%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ARDX have?

    As of the end of the reporting period, Ardelyx, inc. (ARDX) had total debt of 207.95M, with a debt ratio of 0.41. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ARDX have?

    At the end of the period, Ardelyx, inc. (ARDX) held Total Cash and Cash Equivalents of 68M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ARDX go with three margins increasing?

    In the latest report, Ardelyx, inc. (ARDX) did not achieve the “three margins increasing” benchmark, with a gross margin of 91.3%%, operating margin of 4.07%%, and net margin of -0.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ARDX's profit trajectory and future growth potential.

  • Is ARDX's EPS continuing to grow?

    According to the past four quarterly reports, Ardelyx, inc. (ARDX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ARDX?

    Ardelyx, inc. (ARDX)'s Free Cash Flow (FCF) for the period is 20.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 123.39% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ARDX?

    The latest valuation data shows Ardelyx, inc. (ARDX) has a Price-To-Earnings (PE) ratio of -26.83 and a Price/Earnings-To-Growth (PEG) ratio of 15.17. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.